Bivalirudin For Pci In Patients With Unstable Angina Or Myocardial Infarction Therapeutics
1. Angiomax patent expiration
Treatment: Inhibition of thrombin in a patient
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5196404 (Pediatric) | SANDOZ | Inhibitors of thrombin |
Jun, 2015
(10 years ago) | |
| US5196404 | SANDOZ | Inhibitors of thrombin |
Dec, 2014
(11 years ago) | |
| US7582727 | SANDOZ | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jul, 2028
(2 years from now) | |
| US7598343 | SANDOZ | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jul, 2028
(2 years from now) | |
|
US7582727 (Pediatric) | SANDOZ | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jan, 2029
(3 years from now) | |
|
US7598343 (Pediatric) | SANDOZ | Pharmaceutical formulations of bivalirudin and processes of making the same |
Jan, 2029
(3 years from now) | |
Drugs and Companies using BIVALIRUDIN ingredient
Market Authorisation Date: 15 December, 2000
Dosage: INJECTABLE
How can I launch a generic of ANGIOMAX before it's drug patent expiration?
More Information on Dosage
ANGIOMAX family patents
